Affordable Access

Publisher Website

Topical minoxidil: Review of efficacy

Authors
Journal
Clinics in Dermatology
0738-081X
Publisher
Elsevier
Publication Date
Volume
6
Issue
4
Identifiers
DOI: 10.1016/0738-081x(88)90087-9
Keywords
  • Clinical Aspects
Disciplines
  • Pharmacology

Abstract

Abstract Hypertrichosis occurs as an undesirable adverse reaction in the majority of hypertensive patients treated with minoxidil (Loniten tablets, Upjohn Company, Kalamazoo, MI). 1–3 Nevertheless, its potential topical use for the treatment of alopecia 4 has caused much publicity and interest in several topical formulations of minoxidil recently available to selected patient populations. First, patients have participated in sanctioned Investigational New Drug studies using unique investigational formulations of The Upjohn Company. Secondly, patients have received Upjohn's topical 2% minoxidil solution marketed in a country outside of the United States, such as Canada. Lastly, patients have had a local pharmacist prepare an extemporaneous minoxidil solution from Loniten tablets. 5,6 The pharmacodynamics of such extemporaneous preparations are variable and may not be directly comparable to Upjohn's unique marketed product. Consequently in 1985, the Food and Drug Administration (FDA) issued an order to halt the use of Loniten Tablets for preparing extemporaneous topical minoxidil solutions for alopecia 5; however, such nonapproved usage constituted by far the major route of exposure to topical minoxidil. 7

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Topical minoxidil: review of efficacy.

on Clinics in dermatology 1988

Topical Minoxidil: Systematic Review and Meta-Anal...

on SKINmed Dermatology for the Cl... 2015
More articles like this..